REMARKS

No new matter has been added by virtue of this Amendment and accompanying Substitute Sequence Listing. The changes made to the specification only reflect the insertion of SEQ ID NO: identifiers. An appendix to this letter shows the specific changes made to the originally filed specification.

Submitted with this Amendment are: (1) a paper copy of the Substitute Sequence Listing containing SEQ ID NO:1 through SEQ ID NO:25; (2) a diskette containing the Substitute Sequence Listing; (3) a "Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 C.F.R. §§1.821-1.825"; and (4) a copy of the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed March 22, 2002. Applicants respectfully request consideration and entry of the Amendment and the Substitute Sequence Listing.

Respectfully submitted,

BIERMAN, MUSERLIAN & LUCAS

Date: July 3 , 2002

By: _____

Charles A. Muserlian

Registration No. 19,683

Correspondence Address:
BIERMAN, MUSERLIAN AND LUCAS, L.L.P
600 Third Avenue, 28th Floor
New York, New York 10016
Telephone: (212) 661-8000
Facsimile: (212) 661-8002

APPENDIX:

Version of Specification Amendments Detailing Additions (Underlined Text) and Deletions (Bracketed Text)

The originally-filed specification has been amended by the addition of SEQ ID NO: identifiers, as shown below:

Sections 'a' and 'b' on page 24, lines 21-29, has been amended as follows:

a. $CD4^+$ T cell epitope used in MAG

PV (poliovirus) sequence 103-115: KLFAVWKITYKDT (SEQ ID NO:4)

-M5: NGKLIAYPIAVEALS (SEQ ID NO:5)

b. Example of "Universal" $CD4^+$ T cell epitopes

-TT (tetanus toxin) derived T cell epitope such as sequence 830-844: QYIKANSKFIGITEL (SEQ ID NO:1) (Panina Bordignon, et al., 1989, Reece, et al., 1993)

-PADRE (Pan DR T Helper epitope): aKXVAAWTLKAAa (a = D-Ala, X = L-cyclohexyl-Ala) (SEQ ID NO:6) (Alexander, et al., 1994)

The paragraph on page 43, lines 21-26, has been amended as follows:

As shown in figure 8 the MAG synthesized is composed of a dendrimeric lysine core structure with four arms. Each arm is linked to a $CD4^+$ T cell epitope (PV peptide: KLFAVWKITYKDT (SEQ ID NO:4) sequence from the poliovirus type 1; (Lo-Man et al. (1996)) with a single α-N-acetylgalactosamine-serine residue (Tn) at the NH_2 terminus [MAG:Tn-PV: $(Ser(\alpha\text{–}GalNAc)]_4\text{-}K_2\text{-}K\text{-}\beta Ala$; Bay et al. (1997))].

The Table on page 55 has been amended as follows:

TABLEAU 3: STRUCTURE OF THE DIFFERENT GLYCOPEPTIDES

$STTTG_6KG$	STTGGGGGGKG (SEQ ID NO:17)
Tn_3G_6KG	S*T*T*GGGGGGKG (SEQ ID NO:18)
Tn_3G_6K(Biot)G	S*T*T*GGGGGGK(Biotine)G (SEQ ID NO:19)
$KG_4Tn_3G_3$	KGGGGS*T*T*GGG (SEQ ID NO:20)
PV	KLFAVWKITYKDT (SEQ ID NO:4)
Tn-PV	S*KLFAVWKITYKDT (SEQ ID NO:21)
Tn_3-PV	S*T*T*KLFAVWKITYKDT (SEQ ID NO:22)
D-(Tn_3)-PV	D-(S*)D-(S*)D-(S*)KLFAVWKITYKDT (SEQ ID NO:23)
Tn_6-PV	$(S*T*T*G)_2$KLFAVWKITYKDT (SEQ ID NO:24)
Tn_3-TT	S*T*T*QYIKANSKIGITEL (SEQ ID NO:25)

The paragraph on page 68, lines 10-11, has been amended as follows:

(PV = KLFAVWKITYKDT (SEQ ID NO:4), M5 - NGKLIAYPIAVEALS (SEQ ID NO:5))

*MAP:PV2 corresponds to the addition of STT unglycosylated aa added to the PV sequence